Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

FDA Seeks Meeting With Sanofi Executives After Warning on Plants

Don't Miss Out —
Follow us on:

July 24 (Bloomberg) -- Inspectors found “significant objectionable conditions” at Sanofi vaccine plants in Canada and France, the U.S. Food and Drug Administration said.

Regulators summoned Olivier Charmeil, the Paris-based drugmaker’s head of vaccines, and other senior executives for a meeting to discuss the issues, the agency said in a July 12 letter to Charmeil made public today. The Sanofi Pasteur vaccines unit is taking steps to address the FDA’s comments and has confidence in products made at the facilities, the company said in an e-mailed statement.

The FDA cited 24 instances in which a Toronto plant failed to meet good manufacturing practices, including failure to follow appropriate procedures to prevent drug contamination. Two violations were found at a factory in Marcy l’Etoile, France, according to the letter.

Sanofi voluntarily recalled four batches of Bacillus Calmette-Guerin tuberculosis vaccine because the product’s sterility can’t be assured, Australia’s drugs regulator said last month. The vaccine was also recalled in Canada and New Zealand, while manufacturing at a plant in Toronto was suspended for renovation and to improve environmental quality management within the building, Patricia Waghorn, Sanofi’s head of communications for Australia and New Zealand, said at the time.

“Sanofi Pasteur takes the observations outlined in the recent FDA warning letter seriously,” Charmeil said in the e-mailed statement. “We are working diligently with the FDA to implement a series of immediate and ongoing steps to address their concerns and further strengthen our global manufacturing operations and quality systems. I have full confidence in our products in the market.”

To contact the reporter on this story: Albertina Torsoli in Paris at atorsoli@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.